{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:15:07Z","timestamp":1771661707497,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T00:00:00Z","timestamp":1456876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.rmed.2016.02.012","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T02:16:43Z","timestamp":1456885003000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Effect of tiotropium on COPD exacerbations: A systematic review"],"prefix":"10.1016","volume":"114","author":[{"given":"David M.G.","family":"Halpin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Metzdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-3814","authenticated-orcid":false,"given":"Frank","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Anzueto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2016.02.012_bib1","series-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2015"},{"key":"10.1016\/j.rmed.2016.02.012_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1465-9921-12-161","article-title":"Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis","volume":"12","author":"Jones","year":"2011","journal-title":"Respir. Res."},{"issue":"6","key":"10.1016\/j.rmed.2016.02.012_bib3","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1183\/09031936.00109906","article-title":"Exacerbations of chronic obstructive pulmonary disease","volume":"29","author":"Celli","year":"2007","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.rmed.2016.02.012_bib4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease","volume":"60","author":"Soler-Cataluna","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2016.02.012_bib5","doi-asserted-by":"crossref","first-page":"29s","DOI":"10.1183\/09031936.03.00078203","article-title":"The burden of illness and economic evaluation for COPD","volume":"41","author":"Ramsey","year":"2003","journal-title":"Eur. Respir. J. Suppl."},{"issue":"12","key":"10.1016\/j.rmed.2016.02.012_bib6","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2016.02.012_bib7","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1183\/09031936.04.00121404","article-title":"Impact of preventing exacerbations on deterioration of health status in COPD","volume":"23","author":"Spencer","year":"2004","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.rmed.2016.02.012_bib8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.rmed.2016.02.012_bib9","first-page":"409","article-title":"Pharmacological treatment of chronic obstructive pulmonary disease","volume":"1","author":"Montuschi","year":"2006","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2016.02.012_bib10","series-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2016"},{"key":"10.1016\/j.rmed.2016.02.012_bib11","first-page":"CD009285","article-title":"Tiotropium versus placebo for chronic obstructive pulmonary disease","volume":"7","author":"Karner","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.rmed.2016.02.012_bib12","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.rmed.2010.06.004","article-title":"A\u00a0one-year trial of tiotropium Respimat plus usual therapy in COPD patients","volume":"104","author":"Bateman","year":"2010","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2016.02.012_bib13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1378\/chest.12-2613","article-title":"Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial","volume":"144","author":"Cooper","year":"2013","journal-title":"Chest"},{"issue":"15","key":"10.1016\/j.rmed.2016.02.012_bib14","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A\u00a04-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"12","key":"10.1016\/j.rmed.2016.02.012_bib15","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.rmed.2016.02.012_bib16","series-title":"Summary of Product Characteristics (SPC): Spiriva 18 Microgram Inhalation Powder, Hard Capsule","author":"Boehringer Ingelheim Limited","year":"2015"},{"key":"10.1016\/j.rmed.2016.02.012_bib17","series-title":"Summary of Product Characteristics (SPC): Spiriva Respimat 2.5 Microgram Inhalation Solution","author":"Boehringer Ingelheim Limited","year":"2015"},{"key":"10.1016\/j.rmed.2016.02.012_bib18","doi-asserted-by":"crossref","first-page":"46s","DOI":"10.1183\/09031936.03.00078002","article-title":"COPD exacerbations: definitions and classifications","volume":"41","author":"Burge","year":"2003","journal-title":"Eur. Respir. J. Suppl."},{"issue":"6","key":"10.1016\/j.rmed.2016.02.012_bib19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","article-title":"Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials","volume":"2","author":"Decramer","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.rmed.2016.02.012_bib20","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.rmed.2014.10.002","article-title":"Efficacy and safety of umeclidinium\/vilanterol 62.5\/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial","volume":"108","author":"Maleki-Yazdi","year":"2014","journal-title":"Respir. Med."},{"issue":"8","key":"10.1016\/j.rmed.2016.02.012_bib21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.rmed.2016.02.012_bib22","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.rmed.2013.02.005","article-title":"Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD","volume":"107","author":"Abrahams","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2016.02.012_bib23","first-page":"197","article-title":"Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies","volume":"5","author":"Bateman","year":"2010","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"5","key":"10.1016\/j.rmed.2016.02.012_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/thorax.58.5.399","article-title":"Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD","volume":"58","author":"Brusasco","year":"2003","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.rmed.2016.02.012_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A\u00a0long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"Casaburi","year":"2002","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.rmed.2016.02.012_bib26","first-page":"465","article-title":"A\u00a0randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease","volume":"14","author":"Chan","year":"2007","journal-title":"Can. Respir. J."},{"issue":"9696","key":"10.1016\/j.rmed.2016.02.012_bib27","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(09)61298-8","article-title":"Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial","volume":"374","author":"Decramer","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.rmed.2016.02.012_bib28","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.rmed.2011.04.002","article-title":"Premature discontinuation during the UPLIFT study","volume":"105","author":"Decramer","year":"2011","journal-title":"Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2016.02.012_bib29","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","article-title":"Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2016.02.012_bib30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1183\/09031936.06.00062705","article-title":"The effect of tiotropium on exacerbations and airflow in patients with COPD","volume":"27","author":"Dusser","year":"2006","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2016.02.012_bib31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1440-1843.2011.01982.x","article-title":"Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial","volume":"16","author":"Fukuchi","year":"2011","journal-title":"Respirology"},{"key":"10.1016\/j.rmed.2016.02.012_bib32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1465-9921-12-6","article-title":"Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial","volume":"12","author":"Hanania","year":"2011","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.rmed.2016.02.012_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2011.09.002","article-title":"Benefits of adding fluticasone propionate\/salmeterol to tiotropium in moderate to severe COPD","volume":"106","author":"Hanania","year":"2012","journal-title":"Respir. Med."},{"issue":"11","key":"10.1016\/j.rmed.2016.02.012_bib34","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.rmed.2010.07.016","article-title":"COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT)","volume":"104","author":"Morice","year":"2010","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2016.02.012_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-143-5-200509060-00007","article-title":"Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial","volume":"143","author":"Niewoehner","year":"2005","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.rmed.2016.02.012_bib36","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/09031936.00023907","article-title":"Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD","volume":"30","author":"Powrie","year":"2007","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2016.02.012_bib37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.trsl.2008.05.011","article-title":"Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease","volume":"152","author":"Rice","year":"2008","journal-title":"Transl. Res."},{"issue":"19","key":"10.1016\/j.rmed.2016.02.012_bib38","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.3760\/cma.j.issn.0366-6999.20130415","article-title":"Evaluation of the efficacy and safety of tiotropium bromide (5 microg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease","volume":"126","author":"Tang","year":"2013","journal-title":"Chin. Med. J. Engl."},{"issue":"10","key":"10.1016\/j.rmed.2016.02.012_bib39","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.rmed.2010.03.033","article-title":"Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial","volume":"104","author":"Tashkin","year":"2010","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2016.02.012_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/COPD.S2463","article-title":"Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD","volume":"3","author":"Tonnel","year":"2008","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2016.02.012_bib41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1183\/09031936.00127809","article-title":"Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial","volume":"36","author":"Troosters","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2016.02.012_bib42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.rmed.2012.09.015","article-title":"Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients","volume":"107","author":"Vogelmeier","year":"2013","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2016.02.012_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2016.02.012_bib44","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2016.02.012_bib45","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00040712","article-title":"Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study","volume":"40","author":"Kerwin","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2016.02.012_bib46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","article-title":"Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium","volume":"182","author":"Donohue","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"16","key":"10.1016\/j.rmed.2016.02.012_bib47","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa1303342","article-title":"Tiotropium Respimat inhaler and the risk of death in COPD","volume":"369","author":"Wise","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"11","key":"10.1016\/j.rmed.2016.02.012_bib48","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.rmed.2007.06.009","article-title":"Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in\u00a0vitro","volume":"101","author":"Buhling","year":"2007","journal-title":"Respir. Med."},{"issue":"6 Pt 1","key":"10.1016\/j.rmed.2016.02.012_bib49","first-page":"L970","article-title":"Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity","volume":"274","author":"Sato","year":"1998","journal-title":"Am. J. Physiol."},{"issue":"2","key":"10.1016\/j.rmed.2016.02.012_bib50","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/jpet.109.152470","article-title":"Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs","volume":"330","author":"Casarosa","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.rmed.2016.02.012_bib51","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2147\/TCRM.S84151","article-title":"Pharmacologic rationale underlying the therapeutic effects of tiotropium\/olodaterol in COPD","volume":"11","author":"Pelaia","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"issue":"21","key":"10.1016\/j.rmed.2016.02.012_bib52","doi-asserted-by":"crossref","first-page":"8746","DOI":"10.1021\/jm401219y","article-title":"Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor","volume":"56","author":"Tautermann","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"issue":"2","key":"10.1016\/j.rmed.2016.02.012_bib53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/2040622313518227","article-title":"Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases","volume":"5","author":"Alagha","year":"2014","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"3","key":"10.1016\/j.rmed.2016.02.012_bib54","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12031-013-0127-0","article-title":"Novel insights into M3 muscarinic acetylcholine receptor physiology and structure","volume":"53","author":"Kruse","year":"2014","journal-title":"J.\u00a0Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.rmed.2016.02.012_bib55","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S2213-2600(13)70248-0","article-title":"Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial","volume":"2","author":"Rabe","year":"2014","journal-title":"Lancet Respir. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611116300300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611116300300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:33:26Z","timestamp":1760614406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611116300300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":55,"alternative-id":["S0954611116300300"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2016.02.012","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of tiotropium on COPD exacerbations: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2016.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}